Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Affiliations

• ¹ Myeloma Service and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. mailanks@mskcc.org.
• ² Department of Medicine, Weill Cornell Medical College, New York, NY, USA. mailanks@mskcc.org.
• ³ Colorado Blood Cancer Institute, Denver, CO, USA.
• ⁴ Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
• ⁵ Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA.
• ⁶ Division of Bone Marrow Transplantation and Cellular Therapy, Stanford University Hospital, Stanford, CA, USA.
• ⁷ Vanderbilt University Medical Center, Nashville, TN, USA.
• ⁸ Bone Marrow Transplant and Cellular Therapy Program, Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX, USA.
• ⁹ Banner MD Anderson Cancer Center, Gilbert, AZ, USA.
• ¹⁰ Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
• ¹¹ Texas Transplant Institute, San Antonio, TX, USA.
• ¹² Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA, USA.
• ¹³ Allogene Therapeutics, South San Francisco, CA, USA.
• ¹⁴ Mayo Clinic, Rochester, MN, USA.